CONTEXT: Focal adhesion kinase (FAK) and Src are overexpressed and activated in many cancers and have been associated with tumor progression. The role of the Src-FAK complex has not been characterized in papillary and anaplastic thyroid cancer (PTC and ATC). OBJECTIVE: The goal of this study was to determine the role of Src and FAK in the growth and invasion of PTC and ATC. DESIGN: PTC and ATC cells were treated with the oral Src inhibitor, AZD0530, to determine the consequences of Src inhibition using growth and invasion assays. FAK and phospho-FAK levels were analyzed in cell lines as well as in PTC tumor samples. RESULTS: AZD0530 treatment inhibited the growth and invasion in four of five thyroid cancer cell lines, and inhibition did not correlate with basal levels of phospho-Src. Instead, we show for the first time that FAK, a critical substrate and effector of Src, is phosphorylated at tyrosine residue 861 (pY861) in PTC and ATC cells, and high levels of phospho-FAK correlate with AZD0530 sensitivity. We further showed that pY861-FAK phosphorylation is Src-dependent. Sensitivity to AZD0530 was confirmed using a preclinical three-dimensional culture model. Phospho-ERK1/2 was not affected by AZD0530, indicating that Src signaling does not require MAPK. Finally, FAK and pY861-FAK were expressed in 10 of 10 and five of 10 PTC tumors, respectively. CONCLUSIONS: Inhibition of the Src-FAK complex represents a promising therapeutic strategy for patients with advanced thyroid cancer, and phospho-FAK represents a potential biomarker for response.
CONTEXT: Focal adhesion kinase (FAK) and Src are overexpressed and activated in many cancers and have been associated with tumor progression. The role of the Src-FAK complex has not been characterized in papillary and anaplastic thyroid cancer (PTC and ATC). OBJECTIVE: The goal of this study was to determine the role of Src and FAK in the growth and invasion of PTC and ATC. DESIGN: PTC and ATC cells were treated with the oral Src inhibitor, AZD0530, to determine the consequences of Src inhibition using growth and invasion assays. FAK and phospho-FAK levels were analyzed in cell lines as well as in PTC tumor samples. RESULTS:AZD0530 treatment inhibited the growth and invasion in four of five thyroid cancer cell lines, and inhibition did not correlate with basal levels of phospho-Src. Instead, we show for the first time that FAK, a critical substrate and effector of Src, is phosphorylated at tyrosine residue 861 (pY861) in PTC and ATC cells, and high levels of phospho-FAK correlate with AZD0530 sensitivity. We further showed that pY861-FAK phosphorylation is Src-dependent. Sensitivity to AZD0530 was confirmed using a preclinical three-dimensional culture model. Phospho-ERK1/2 was not affected by AZD0530, indicating that Src signaling does not require MAPK. Finally, FAK and pY861-FAK were expressed in 10 of 10 and five of 10 PTC tumors, respectively. CONCLUSIONS: Inhibition of the Src-FAK complex represents a promising therapeutic strategy for patients with advanced thyroid cancer, and phospho-FAK represents a potential biomarker for response.
Authors: Giuliana Salvatore; Valentina De Falco; Paolo Salerno; Tito Claudio Nappi; Stefano Pepe; Giancarlo Troncone; Francesca Carlomagno; Rosa Marina Melillo; Scott M Wilhelm; Massimo Santoro Journal: Clin Cancer Res Date: 2006-03-01 Impact factor: 12.531
Authors: Bin Ouyang; Jeffrey A Knauf; Eric P Smith; Lei Zhang; Tim Ramsey; Naeem Yusuff; David Batt; James A Fagin Journal: Clin Cancer Res Date: 2006-03-15 Impact factor: 12.531
Authors: Rebecca E Schweppe; Joshua P Klopper; Christopher Korch; Umarani Pugazhenthi; Miriam Benezra; Jeffrey A Knauf; James A Fagin; Laura A Marlow; John A Copland; Robert C Smallridge; Bryan R Haugen Journal: J Clin Endocrinol Metab Date: 2008-08-19 Impact factor: 5.958
Authors: Sang Jin Kim; Jin Woo Park; Ji Sung Yoon; Ji O Mok; Yeo Joo Kim; Hyeong Kyu Park; Chul Hee Kim; Dong Won Byun; Yong Jin Lee; So Young Jin; Kyo Il Suh; Myung Hi Yoo Journal: J Korean Med Sci Date: 2004-10 Impact factor: 2.153
Authors: Natsuko Suwaki; Elsa Vanhecke; Katelyn M Atkins; Manuela Graf; Katherine Swabey; Paul Huang; Peter Schraml; Holger Moch; Amy Mulick Cassidy; Daniel Brewer; Bissan Al-Lazikani; Paul Workman; Johann De-Bono; Stan B Kaye; James Larkin; Martin E Gore; Charles L Sawyers; Peter Nelson; Tomasz M Beer; Hao Geng; Lina Gao; David Z Qian; Joshi J Alumkal; Gary Thomas; George V Thomas Journal: Sci Transl Med Date: 2011-06-01 Impact factor: 17.956
Authors: D Chan; J W Tyner; W J Chng; C Bi; R Okamoto; J Said; B D Ngan; G D Braunstein; H P Koeffler Journal: Oncol Lett Date: 2012-01-20 Impact factor: 2.967
Authors: Hai T Ngo; Abdel Kareem Azab; Mena Farag; Xiaoying Jia; Molly M Melhem; Judith Runnels; Aldo M Roccaro; Feda Azab; Antonio Sacco; Xavier Leleu; Kenneth C Anderson; Irene M Ghobrial Journal: Clin Cancer Res Date: 2009-09-15 Impact factor: 12.531
Authors: Rebecca E Schweppe; Nikita Pozdeyev; Laura A Pike; Christopher Korch; Qiong Zhou; Sharon B Sams; Vibha Sharma; Umarani Pugazhenthi; Christopher Raeburn; Maria B Albuja-Cruz; Philip Reigan; Daniel V LaBarbera; Iñigo Landa; Jeffrey A Knauf; James A Fagin; Bryan R Haugen Journal: Mol Cancer Res Date: 2019-02-07 Impact factor: 5.852
Authors: Brittelle E Kessler; Vibha Sharma; Qiong Zhou; Xia Jing; Laura A Pike; Anna A Kerege; Sharon B Sams; Rebecca E Schweppe Journal: Mol Cancer Res Date: 2016-06-03 Impact factor: 5.852
Authors: Ying C Henderson; Rafael Toro-Serra; Yunyun Chen; Junsun Ryu; Mitchell J Frederick; Ge Zhou; Gary E Gallick; Stephen Y Lai; Gary L Clayman Journal: Head Neck Date: 2013-06-01 Impact factor: 3.147